We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.

Delisted

EIGR was delisted on the 10th of April, 2024.

1 hedge funds and large institutions have $765K invested in Eiger BioPharmaceuticals, Inc. in 2024 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 11 (0)

39% less capital invested

Capital invested by funds: $1.24M → $765K (-$479K)

Holders
1
Holders Change
Holders Change %
0%
% of All Funds
0.01%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change
Change in
Stake
PBM
1
Propel Bio Management
California
$765K

EIGR Hedge Fund Activity: Q4 2024 in Review

1 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q4 2024, worth a combined $765K — down 39% from $1.24M a quarter earlier.

Fund positioning in EIGR was balanced in Q4 2024: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $765K of Eiger BioPharmaceuticals, Inc. stock for Q4 2024, down 39% quarter-over-quarter.
  • 0 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q4 2024 and 0 closed out.

Based on aggregated 13F filings for Q4 2024.